osteoporosis
DESCRIPTION
concepts and controversies in osteoporosisTRANSCRIPT
Osteoporosis: Best EvidenceHitesh Gopalan U
Clinical Assistant Prof,Visiting Lecturer, McMaster University, CA
Classification
WHO DefinitionBone density that falls 2.5 standard
deviations (SD) below the mean for young healthy adults of the same sex—also referred to as a T-score of –2.5
LabSerum CaPTH25(OH) Vit DUrine Ca
High serum Ca (Hyperparathyroidism Vs Malignancy)
Low serum Ca (Osteomalacia)
HypercalciURIA: males with osteoporosis, Hyperparathyroidism, Paget’s disease, Hyperthyroidism
Secondary OsteoporosisHypogonadal States: Turner, KlinefleterEndocrine conditions: Thyrotoxicosis,
Cushing’sGI conditions: Gastrectomy, Liver diseaseRheumatological: RA, ASHematologic Disorders: Multiple MyelomaInherited Conditions: OI, Marfan
DEXACT ScanX-rays
TreatmentEstrogen- beneficial- ↑ risk of Endometrial
Ca
Estrogen + Progesterone= ↑ Risk of heart disease/stroke
Tibolone
What we Know
SERMRaloxifene
Reduces risk of vertebral fractures
Reduced incidence of Ca Breast, Cardiovascular and Cerebrovascular Events
BisphosphonatesAlendronate
Ibandronate
Risedronate
Zolendronic Acid
BisphosphonatesOsteonecrosis of Jaw, Atypical
Subtrochanteric Fractures
? Ca oesophagus
Perthe’s Disease, Osteogenesis Imperfecta, AVN
Accumulates in the Body
Bisphosphonates- # HealingIncrease BMD at # site- Single Dose
Does not interfere with fracture healing
Odvina et al.. J Clin Endocrinol Metab2005;90(3):1294–301.van der Poest Clement E, J Bone Miner Res 2000;15(3):586–93.
TeriparatideRecombinant PTH
Daily injection
Cost
Osteogenic Ca
CalcitoninNasal Spray
Paget’s Disease
Kyphoplasty Vs Sham
Denosumab
FREEDOMFracture Reduction Evaluation of Denosumab
in Osteoporosis Every 6 Months (FREEDOM) Trial
No major adverse effects
Supported by AMGEN
DenosumabHigher incidence of infections
Contraindicated in Hypocalcemia
VEGF-A
Hierarchy of Evidence
Randomized Trials
Prospective Cohort Studies
Retrospective Case Series
Case Control Studies
Opinion
Meta-analysis
Ask
Acquire
AppraiseApply
Act
“EBM Begins and Ends with the Patient”
Evidence Cycle